Care of HIV-infected patients in China

Cell Research

Volumn 15, Issue 11-12, 2005, Pages 883-890

  Cao, Yun Zhen ^a   Lu, Hong Zhou ^b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

China CARES program; HAART; HIV AIDS; Needle sharing; Unprotected sex

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHINA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CHINA; HIV; HIV INFECTIONS; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 29244463330     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290363     Document Type: Review

References (20)

1. State Council AIDS Working Committee office and UN Theme Group on HIV/AIDS in China. A joint assessment of HIV/AIDS prevention, Treatment and care in China (2004). Beijing, 2004
2. Cao, Y, Li G, Wang SY, et al. Epidemiology, crisis and strategy on HIV mother-to-infant transmission in China. Chi J Infect Dis 2002; 20:185-8
3. Zhuang K, Gui X, Su B, et al. High prevalence of HIV infection among women and their children in Henan Province, China. J AIDS 2003; 33:649-50
4. Ying N, Mei S, Li L, et al. Study on the epidemiology and distribution of Human Immunodeficiency Virus-1 and hepatitis C Virus infection among intravenous drug users and illegal blood donors in China. Chinese Journal of Epidemiology 2003; 24:962-5
5. China's Medium- & Long-term Strategy for HIV/AIDS Prevention and Control (1998-2010). Mministry of Healthy. China. http://www.chinaids.org.cn/ zhq/index.asp
6. China's Action Plan for Reducing and Preventing the Spread of HIV/AIDS (2001-2005). Mministry of Healthy. China, http:// www.chinaids.org.cn/zhq/index. asp
7. Drugs Used in the Treatment of HIV infection. http://www.fda. gov/oashi/aids/virals.html
8. Cao Y, Zhang F, Mei S, et al. The first clinical trial in China using triple therapy Combivir plus Indinavir in patients with HIV-1 infection. Chinese Medical Journal, Electronic Version 2002; 115(10). http://www.cmj.org.
9. Wang Q, Wei F, Mei S, et al. Assessing the safety and efficacy of HAART regimens over four years of therapy. Chinese Journal of Infectious Diseases. In press.
10. Li L, Wei F, Mei S, et al. 48 weeks follow-up the virological and immunological outcomes in combination therapy with Efavirenz and Indinavir in HIV-1 infectious in China. Chinese Journal of STD/AIDS Prevention and Control 2002; 8:326-30.
11. Li L , Wei F, Mei S, et al. Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks. Chinese Medical Journal 2004; 117:347-52
12. Li L, Wei F, Mei S, et al. The impact of HAART on immunological parameters in HIV-1-infected Chinese, International AIDS Conference, Bangkok, 2004. MOPE A 3010.
13. th ICAAC Meeting, 2005
14. China Free ART Manual, Division of Treatment and Care, NCAIDS, CDC, MOH. China. 2005.
15. Paterson DL, Swindells S. Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
16. Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the Clinical Efficacy of Resistance Testing trial. Clin Infect Dis 2004; 38:723-30
17. Wei F, Gao L, Mei S, et al. The report of resistance assay after long term HAART from 19 HIV/AIDS cases. Xiamen, China: National Infectious conference, 2005.
18. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of Antiretro viral Resistance in HIV-Positive Women Receiving Combination Antiretroviral Therapy in Pregnancy. AIDS 2005; 19:63-67.
19. Holmberg SD, Jr Palella FJ, Lichtenstein KA, et al. The Case for Earlier Treatment of HIV Infection. Clin Infect Dis 2004; 39:1699-704.
20. Cohen CJ, Boyle BA. Antiretroviral Therapy: The "When to Start" Debates, Editorial Commentary, Clin Infect Dis 2004; 39:1705-8.